Apimeds Pharmaceuticals US, Inc. (APUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has a cash flow conversion efficiency ratio of -0.212x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.73 Million) by net assets ($8.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Apimeds Pharmaceuticals US, Inc. (APUS) net asset quality to measure how much of total assets are equity-financed.
Apimeds Pharmaceuticals US, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Apimeds Pharmaceuticals US, Inc. service its debt to assess how comfortably operating cash covers total debt obligations.
Apimeds Pharmaceuticals US, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Nordic Healthbrands AB (publ)
ST:NNH
|
-0.107x |
|
Together Startup Network Ltd
TA:TGTR
|
-0.149x |
|
Roman DBDR Acquisition Corp. II Warrants
NASDAQ:DRDBW
|
N/A |
|
Bekasi Asri Pemula Tbk
JK:BAPA
|
-0.003x |
|
ALERIO GOLD CORP.
F:3FR0
|
N/A |
|
FGI Industries Ltd
NASDAQ:FGI
|
-0.023x |
|
Giga Metals Corp
V:GIGA
|
-0.012x |
|
Canterbury Resources Ltd
AU:CBY
|
-0.060x |
Annual Cash Flow Conversion Efficiency for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Apimeds Pharmaceuticals US, Inc. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see APUS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.36 Million | $-733.53K | 0.540x | +102.74% |
| 2023-12-31 | $31.87K | $-627.79K | -19.698x | -3236.44% |
| 2022-12-31 | $-713.61K | $-448.17K | 0.628x | -81.80% |
| 2021-12-31 | $-238.48K | $-823.11K | 3.451x | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.